




RealRate

PHARMACEUTICAL 2024

Gain Therapeutics Inc
Rank 181 of 309

GAIN
THERAPEUTICS



The relative strengths and weaknesses of Gain Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Gain Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 45% points. The greatest weakness of Gain Therapeutics Inc is the variable Net Income, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is 181%, being 32% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	17,779
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,950
Liabilities, Non-Current	1,081
Other Assets	705
Other Compr. Net Income	0
Other Expenses	79
Other Liabilities	0
Other Net Income	65
Other Revenues	55
Property and Equipment	126
Research and Development	11,521
Selling, General and Administrative Expense	10,788

Output Variable	Value in 1000 USD
Assets	18,609
Liabilities	6,031
Expenses	22,388
Revenues	55
Stockholders Equity	12,578
Net Income	-22,268
Comprehensive Net Income	-22,268
BaseVar	23,574
ECR before LimitedLiability	42%
Economic Capital Ratio	181%